Cosmo NV (LTS:0RGI)

Full Year 2024 Cosmo Pharmaceuticals NV Earnings Call Transcript

Mar 6, 2025 / 02:00 PM GMT

Release Date Price: CHF57.1 (-12.02%)

Transcript

Key Points

Positve

Cosmo Pharmaceuticals NV (CMOPF) reported record revenues and operating profit for 2024, marking a transformational year.
The company maintains a strong cash position with zero debt, providing financial stability and flexibility.
Cosmo Pharmaceuticals NV (CMOPF) secured two FDA approvals in 2024, reinforcing its competence in navigating regulatory pathways.
The company has a robust pipeline with significant growth potential, including a major upcoming catalyst in the male hair loss market.
Cosmo Pharmaceuticals NV (CMOPF) is expanding its AI-driven endoscopy platform, GI Genius, into new areas, enhancing its market position.

Negative

The company changed its accounting policy regarding internal development costs, impacting operating expenses.
Despite strong financial results, the share price declined by 11% following the announcement, indicating potential investor concerns.
Cosmo Pharmaceuticals NV (CMOPF) provided a lower revenue guidance for 2025 compared to previous expectations, focusing on strategic value.
The company faces potential challenges in securing partnerships for its phase 3 trial assets, impacting future commercialization strategies.
There are uncertainties regarding the impact of potential tariffs from the US administration on the company's operations.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

COPN.S - Cosmo Pharmaceuticals NV
Full Year 2024 Cosmo Pharmaceuticals NV Earnings Call
Mar 06, 2025 / 02:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon everyone and welcome to Cosmo's full year 2024 unauuddied results webcast call. My name is Hazel Winchester, head of investor relations at Cosmo Pharmaceuticals.

Thank you all for joining us today. We are excited to share the results of a strong year and provide insights into the performance of our business along with key strategic initiatives and outlook for the future.

Please note this presentation includes forward-looking statements. While based on current insights, actual results may vary due to risk and uncertainties.

Before we dive into the presentation, I'd also like to remind everyone that the presentation slides for today's webcast are available for download, and a

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.